Table 1.
Demographic characteristics of included patients, grouped by whether patient received liver-directed therapy and the timing of that in relation to their diagnosis of bone metastasis.
| Factors | Group A: Liver-Directed Therapy Prior to Diagnosis of Bone Metastasis n (%) |
Group B: Liver-Directed Therapy after Diagnosis of Bone Metastasis n (%) |
Group C: No Liver-Directed Therapy n (%) |
|---|---|---|---|
| Patients | 45 (22.1) | 30 (14.8) | 128 (63.1) |
| Age in years, mean ± SD | 54.0 ± 12.3 | 54.7 ± 14.2 | 59.6 ± 13.5 |
| Male | 24 (53.3) | 16 (33.3) | 66 (51.6) |
| Race/Ethnicity | |||
| Caucasian | 32 (71.1) | 15 (50) | 74 (57.8) |
| Other | 13 (28.9) | 15 (50) | 54 (42.2) |
| Charlson Comorbidity score | |||
| ≥2 | 11 (24.4) | 18 (60) | 57 (44.5) |
| Primary tumor site | |||
| Pancreas | 20 (44.4) | 11 (36.7) | 57 (44.5) |
| Colorectal | 12 (26.7) | 13 (43.3) | 39 (30.5) |
| Additional sites of metastasis | |||
| Lung | 15 (33.3) | 11 (36.7) | 33 (25.8) |
| Peritoneum and/or brain | 14 (31.1) | 11 (36.7) | 33 (25.8) |
| Grade III histology | 24 (53.3) | 20 (66.7) | 87 (68.0) |
| Received embolization therapy | 40 (89.9) | 30 (100) | - |
| Received chemotherapy | 25 (55.6) | 22 (73.3) | 51 (39.8) |
SD = standard deviation.